Optimising the laboratory supply chain: The key to effective laboratory services

  • Edgil D
  • Williams J
  • Smith P
  • et al.
N/ACitations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Background: The Supply Chain Management System (SCMS) is a contract managed under the Partnership for Supply Chain Management (PFSCM) consortium by the United States Agency for International Development (USAID). SCMS procures commodities for programmes supported by the US President’s Emergency Plan for AIDS Relief (PEPFAR). From 2005 to mid-2012, PEPFAR, through SCMS, spent approximately $384 million on non-pharmaceutical commodities. Of this, an estimated $90m was used to purchase flow cytometry technology, largely for flow cytometry platforms and reagents.Objectives: The purpose of this paper is to highlight the cost differences between low, medium and high utilisation rates of common CD4 testing instruments that have been procured though PEPFAR funding.Method: A scale of costs per test as a function of test volume through the machine was calculated for the two most common CD4 testing machines used in HIV programmes: Becton Dickinson (BD) FACSCount™ and BD FACSCalibur™. Instrument utilisation data collected at the facility level in three selected countries were then used to calculate the onsite cost-per-test experienced in each country.Results: Cost analyses indicated that a target of at least 40% utilisation for FACSCount™ and 15% utilisation for FACSCalibur™, respectively, closely approach maximal per-test cost efficiency. The average utilisation rate for CD4 testing instruments varies widely by country, level of laboratory and partner (0% − 68%).Conclusion: Our analysis indicates that, because cost-per-test is related inversely to sample throughput, the underutilisation of flow cytometry machines is resulting in an increase in average cost-per-test for many instruments.

Figures

  • TABLE 1: CD4 count platform reagents and usage rates.
  • FIGURE 1: Partnership for Supply Chain Management (PFSCM) total spending as of June 30, 2012. PFSCM historical procurement data were used to determine the total expenditures for the Supply Chain Management Systems Life of Project (LOP). All figures represent the value of delivered commodities in US dollars from September 2005 to June 2012. Data are categorised into pharmaceuticals (Pharma [66%], HIV RDTs [9%], Analysers and/or reagents [13%], Lab/clinical supplies [8%] and Other [4%]).
  • FIGURE 2: Partnership for Supply Chain Management (PFSCM) spending on laboratory commodities delivered through June 2012. PFSCM historical procurement data are displayed as expenditures per year from 2007 through June 2012. PEPFAR flow-cytometry expenditures show continual increases on a per-year basis.
  • TABLE 2: FACSCount™ and FACSCalibur™ reagent unit price per test.
  • FIGURE 3: FACSCount™ versus FACCalibur™ utilisation price per test in US dollars. The reagent unit cost-per-test for the BD FACSCount™ and BD FACSCalibur™ instruments was based on historical Partnership for Supply Chain Management (PFSCM) pricing and manufacturer-established consumption amounts,7,8 using the reagents and consumption ratios in Table 1. Total costs were then calculated based on the product requirements needed to conduct CD4 testing over a one-day period. The rate of return diminishes to less than $0.01 per additional test added per day after a critical volume is achieved: FACSCount™, n > 20 tests or 40% throughput; FACSCalibur™, n > 45 tests or 15% throughput.
  • TABLE 3: Country A CD4 Testing Equipment Utilisation.
  • TABLE 4: Country B CD4 Testing Equipment Utilisation.
  • TABLE 5: Country C Comparison of CD4 Testing Equipment Utilisation in 2011 and 2012. For Country C, product use and diagnostic contribution were disaggregated according to those implementing partners using BD instruments (five partners using other brands were removed from the analysis). Total CD4 commodity costs for 2011 were based on actual testing services provided. 2012 unit prices were based on projected programmatic growth and planned instrument procurements. Instrument utilisation rates for Partners 2, 4 and 5 are, respectively, 30%, 4% and 43% in 2011 and 5%, 4% and 57% in 2012, indicating appropriate growth for Partner 5, but a decrease or no increase in efficiency (reduced cost-per-test) for Partners 2 and 4.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Edgil, D., Williams, J., Smith, P., & Kuritsky, J. (2014). Optimising the laboratory supply chain: The key to effective laboratory services. African Journal of Laboratory Medicine, 3(1). https://doi.org/10.4102/ajlm.v3i1.101

Readers over time

‘16‘18‘19‘20‘21‘22‘23036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

46%

Researcher 5

38%

Lecturer / Post doc 2

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

30%

Business, Management and Accounting 3

30%

Social Sciences 2

20%

Economics, Econometrics and Finance 2

20%

Save time finding and organizing research with Mendeley

Sign up for free
0